Classification and Diagnosis of Adult Glioma: A Scoping Review

키워드

참고문헌 (49)

1. Sanai N, "Neural stem cells and the origin of gliomas", N Engl J Med, 353, pp.811~822 (2005)
2. Weller M, "EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood", Nat Rev Clin Oncol, 18, pp.170~186 (2021)
3. 강호, "A Nationwide, Population-Based Epidemiology Study of Primary Central Nervous System Tumors in Korea, 2007-2016: A Comparison with United States Data", Cancer Research and Treatment, 53(2), pp.355~366 (2021), 대한암학회[DOI]
4. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization defines human glioblastoma genes and core pathways", Nature, 455, pp.1061~1068 (2008)
5. Louis DN, "The 2021 WHO classification of tumors of the central nervous system : a summary", Neuro-oncol, 23, pp.1231~1251 (2021)
6. Perez A, "The evolving classification of diffuse gliomas : World Health Organization updates for 2021", Curr Neurol Neurosci Rep, 21, pp.67~ (2021)
7. World Health Organization, "World Health Organization classification of tumours of the central nervous system" (2021), International Agency for Research on Cancer
8. Komori T, "The 2021 WHO classification of tumors, 5th edition, central nervous system tumors : the 10 basic principles", Brain Tumor Pathol, 39, pp.47~50 (2022)
9. Appay R, "CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas", Neuro-oncol, 21, pp.1519~1528 (2019)
10. Tesileanu CMS, "Survival of diffuse astrocytic glioma, IDH1", 2 wildtype, with molecular features of glioblastoma, WHO grade IV : a confirmation of the cIMPACT-NOW criteria, 2020, pp.22, 515~523
11. Gritsch S, "Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system", Cancer, 128, pp.47~58 (2022)
12. Colman H, "Adult gliomas", Continuum(Minneap Minn), 26, pp.1452~1475 (2020)
13. Rasmussen BK, "Epidemiology of glioma : clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry", J Neurooncol, 135, pp.571~579 (2017)
14. Peeters MC, "Prediagnostic symptoms and signs of adult glioma : the patients’ view", J Neurooncol, 146, pp.293~301 (2020)
15. Schmidt-Hansen M, "Symptomatic diagnosis of cancer of the brain and central nervous system in primary care : a systematic review", Fam Pract, 32, pp.618~623 (2015)
16. Taphoorn MJ, "Cognitive deficits in adult patients with brain tumours", Lancet Neurol, 3, pp.159~168 (2004)
17. Posti JP, "Presenting symptoms of glioma in adults", Acta Neurol Scand, 131, pp.88~93 (2015)
18. Badve C, "Radiogenomics of gliomas", Radiol Clin North Am, 59, pp.441~455 (2021)
19. Smits M, "Imaging correlates of adult glioma genotypes", Radiology, 284, pp.316~331 (2017)
20. Carrillo JA, "Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma", AJNR Am J Neuroradiol, 33, pp.1349~1355 (2012)
21. Qi S, "Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms", Oncol Lett, 7, pp.1895~1902 (2014)
22. Smits M, "Update on neuroimaging in brain tumours", Curr Opin Neurol, 34, pp.497~504 (2021)
23. Patel SH, "T2-FLAIR mismatch, an imaging biomarker for IDH and 1p", 19q status in lower-grade gliomas : a TCGA, Clin Cancer Res, pp.2017, 23[DOI]
24. Corell A, "The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas : a population-based study", BMC Cancer, 20, pp.450~ (2020)
25. Gross S, "Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations", J Exp Med, 207, pp.339~344 (2010)
26. Turcan S, "IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype", Nature, 483, pp.479~483 (2012)
27. DeWeerdt S, "The genomics of brain cancer", Nature, 561, pp.S54~S55 (2018)
28. Śledzińska P, "Prognostic and predictive biomarkers in gliomas", Int J Mol Sci, 22, pp.10373~ (2021)
29. Liu XY, "Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1", IDH2 and TP53 mutations, 2012, pp.124, 615~625
30. Bai J, "Adult glioma WHO classification update, genomics, and imaging : what the radiologists need to know", Top Magn Reson Imaging, 29, pp.71~82 (2020)
31. Pacifico A, "Role of p53 and CDKN2A inactivation in human squamous cell carcinomas", J Biomed Biotechnol, 2007, pp.43418~ (2007)
32. Shirahata M, "Novel, improved grading system(s)for IDH-mutant astrocytic gliomas", Acta Neuropathol, 136, pp.153~166 (2018)
33. Van den Bent MJ, "Oligodendroglioma", Crit Rev Oncol Hematol, 66, pp.262~272 (2008)
34. Wesseling P, "Oligodendroglioma : pathology, molecular mechanisms and markers", Acta Neuropathol, 129, pp.809~827 (2015)
35. Jenkins RB, "A t(1;19)(q10;p10)mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma", Cancer Res, 66, pp.9852~9861 (2006)
36. Ostrom QT, "CBTRUS statistical report : primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018", Neuro-oncol, 23, pp.iii1~iii105 (2021)
37. McKinnon C, "Glioblastoma : clinical presentation, diagnosis, and management", BMJ, 374, pp.n1560~ (2021)
38. Alexander BM, "Adult glioblastoma", J Clin Oncol, 35, pp.2402~2409 (2017)
39. An Z, "Epidermal growth factor receptor and EGFRvIII in glioblastoma : signaling pathways and targeted therapies", Oncogene, 37, pp.1561~1575 (2018)
40. Bell RJ, "Understanding TERT promoter mutations : a common path to immortality", Mol Cancer Res, 14, pp.315~323 (2016)
41. Stichel D, "Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma", Acta Neuropathol, 136, pp.793~803 (2018)
42. Thon N, "Personalized treatment strategies in glioblastoma : MGMT promoter methylation status", Onco Targets Ther, 6, pp.1363~1372 (2013)
43. Mansouri A, "MGMT promoter methylation status testing to guide therapy for glioblastoma : refining the approach based on emerging evidence and current challenges", Neuro-oncol, 21, pp.167~178 (2019)
44. Dunbar E, "Glioma diagnosis : immunohistochemistry and beyond", Adv Anat Pathol, 17, pp.187~201 (2010)
45. Tanboon J, "The diagnostic use of immunohistochemical surrogates for signature molecular genetic alterations in gliomas", J Neuropathol Exp Neurol, 75, pp.4~18 (2016)
46. Rodriguez FJ, "Recent advances on the molecular pathology of glial neoplasms in children and adults", J Mol Diagn, 18, pp.620~634 (2016)
47. Synhaeve NE, "Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics", Acta Neuropathol Commun, 6, pp.126~ (2018)
48. Sahm F, "Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets", Acta Neuropathol, 131, pp.903~910 (2016)
49. Behjati S, "What is next generation sequencing?", Arch Dis Child Educ Pract Ed, 98, pp.236~238 (2013)

관련 논문AI추천